Nancy S. Shulman

3.2k total citations
63 papers, 2.2k citations indexed

About

Nancy S. Shulman is a scholar working on Infectious Diseases, Hepatology and Epidemiology. According to data from OpenAlex, Nancy S. Shulman has authored 63 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Infectious Diseases, 35 papers in Hepatology and 32 papers in Epidemiology. Recurrent topics in Nancy S. Shulman's work include HIV/AIDS drug development and treatment (36 papers), Hepatitis C virus research (35 papers) and Hepatitis B Virus Studies (18 papers). Nancy S. Shulman is often cited by papers focused on HIV/AIDS drug development and treatment (36 papers), Hepatitis C virus research (35 papers) and Hepatitis B Virus Studies (18 papers). Nancy S. Shulman collaborates with scholars based in United States, New Zealand and France. Nancy S. Shulman's co-authors include Robert W. Shafer, Andrew Zolopa, Patrick F. Smith, Edward Gane, Isabel Nájera, David Katzenstein, David Bernstein, Paul J. Pockros, Brett Ritchie and Mark A. Winters and has published in prestigious journals such as The Lancet, Blood and Gastroenterology.

In The Last Decade

Nancy S. Shulman

62 papers receiving 2.1k citations

Peers

Nancy S. Shulman
Eoin Coakley United States
Paul Neuwald United States
M. Michelle Berrey United States
Anders Sönnerborg Sweden
Ashwin Balagopal United States
Barbara McGovern United States
Ross Martin United States
Teresa I. Ng United States
Laurence Morand‐Joubert France
Jens Verheyen Germany
Eoin Coakley United States
Nancy S. Shulman
Citations per year, relative to Nancy S. Shulman Nancy S. Shulman (= 1×) peers Eoin Coakley

Countries citing papers authored by Nancy S. Shulman

Since Specialization
Citations

This map shows the geographic impact of Nancy S. Shulman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy S. Shulman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy S. Shulman more than expected).

Fields of papers citing papers by Nancy S. Shulman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy S. Shulman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy S. Shulman. The network helps show where Nancy S. Shulman may publish in the future.

Co-authorship network of co-authors of Nancy S. Shulman

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy S. Shulman. A scholar is included among the top collaborators of Nancy S. Shulman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy S. Shulman. Nancy S. Shulman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lawitz, Eric, Edward Gane, E. Cohen, et al.. (2018). Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. Kidney International Reports. 4(2). 257–266. 17 indexed citations
2.
3.
Wyles, David, Michael S. Saag, Rolando M. Viani, et al.. (2017). TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. The Journal of Infectious Diseases. 215(4). 599–605. 16 indexed citations
4.
Feld, Jordan J., Christophe Moreno, Roger Trinh, et al.. (2015). Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. Journal of Hepatology. 64(2). 301–307. 110 indexed citations
5.
Gane, Edward, Paul J. Pockros, Stefan Zeuzem, et al.. (2014). Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM ‐ SVR study. Liver International. 35(1). 79–89. 23 indexed citations
6.
Flamm, Steven L., Edward Gane, Jean‐François Dufour, et al.. (2014). Safety of ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients >= 65 Years of Age: Results From Phase 2 and 3 Trials. Hepatology. 60. 4 indexed citations
7.
Margeridon‐Thermet, Severine, Sophie Le Pogam, Lewyn Li, et al.. (2014). Similar Prevalence of Low-Abundance Drug-Resistant Variants in Treatment-Naive Patients with Genotype 1a and 1b Hepatitis C Virus Infections as Determined by Ultradeep Pyrosequencing. PLoS ONE. 9(8). e105569–e105569. 14 indexed citations
8.
Hunt, Peter W., Nancy S. Shulman, Timothy L. Hayes, et al.. (2013). The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood. 121(23). 4635–4646. 107 indexed citations
9.
Chu, Tom, Rohit Kulkarni, Edward Gane, et al.. (2012). Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C. Gastroenterology. 142(4). 790–795. 72 indexed citations
10.
11.
Margeridon‐Thermet, Severine, Nancy S. Shulman, Aijaz Ahmed, et al.. (2009). Ultra‐Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse‐Transcriptase Inhibitor (NRTI)–Treated Patients and NRTI‐Naive Patients. The Journal of Infectious Diseases. 199(9). 1275–1285. 176 indexed citations
12.
Kapoor, Amit, Beth Shapiro, Robert W. Shafer, et al.. (2008). Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients. Retrovirology. 5(1). 7–7. 6 indexed citations
13.
Clark, Shauna, Nancy S. Shulman, Ronald J. Bosch, & John W. Mellors. (2006). Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS. 20(7). 981–984. 36 indexed citations
14.
Shulman, Nancy S., Ronald J. Bosch, Mark A. Winters, et al.. (2005). Nonnucleoside Reverse Transcriptase Inhibitor Phenotypic Hypersusceptibility Can Be Demonstrated in Different Assays. JAIDS Journal of Acquired Immune Deficiency Syndromes. 39(1). 78–81. 5 indexed citations
15.
Shulman, Nancy S., Ronald J. Bosch, John W. Mellors, Mary Albrecht, & David Katzenstein. (2004). Genetic correlates of efavirenz hypersusceptibility. AIDS. 18(13). 1781–1785. 42 indexed citations
16.
Lecossier, Denise, Nancy S. Shulman, Laurence Morand‐Joubert, et al.. (2004). Detection of Minority Populations of HIV-1 Expressing the K103N Resistance Mutation in Patients Failing Nevirapine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 38(1). 37–42. 80 indexed citations
17.
Shulman, Nancy S. & Mark A. Winters. (2003). A Review of HIV-1 Resistance to the Nucleoside and Nucleotide Inhibitors. PubMed. 3(4). 273–281. 24 indexed citations
18.
Shulman, Nancy S., Michael D. Hughes, Mark A. Winters, et al.. (2002). Subtle Decreases in Stavudine Phenotypic Susceptibility Predict Poor Virologic Response to Stavudine Monotherapy in Zidovudine-Experienced Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 31(2). 121–127. 23 indexed citations
19.
20.
Shulman, Nancy S., Robert W. Shafer, Mark A. Winters, et al.. (2001). Genotypic Correlates of a Virologic Response to Stavudine After Zidovudine Monotherapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 27(4). 377–380. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eoin Coakley Breakdown of academic impact, for papers by Paul Neuwald Breakdown of academic impact, for papers by M. Michelle Berrey Breakdown of academic impact, for papers by Anders Sönnerborg Breakdown of academic impact, for papers by Ashwin Balagopal Breakdown of academic impact, for papers by Barbara McGovern Breakdown of academic impact, for papers by Ross Martin Breakdown of academic impact, for papers by Teresa I. Ng Breakdown of academic impact, for papers by Laurence Morand‐Joubert Breakdown of academic impact, for papers by Jens Verheyen
Rankless by CCL
2026